Targeting CD38 with Daratumumab for Platelet Transfusion Refractoriness in Aplastic Anemia.

IF 21 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2025-05-07 DOI:10.1182/blood.2025029006

Zhen Gao,Hong Pan,Lele Zhang,Weiwang Li,Ruonan Li,Jingyu Zhao,Yuechen Luo,Yu Lian,Xiao Yu,Zhexiang Kuang,Neng Nie,Jianping Li,Jinbo Huang,Xin Zhao,Yuan Li,Liwei Fang,Meili Ge,Yizhou Zheng,Jun Shi

引用次数: 0

Abstract

We found that 8 out of 10 aplastic anemia patients experienced resolution of platelet transfusion refractoriness following daratumumab administration. Notably, 4 responders achieved hematopoietic recovery, including 3 participants showed improvements in multi-lineage blood cell counts, even with daratumumab monotherapy (NCT05832216).

查看原文本刊更多论文

靶向CD38的达拉单抗治疗再生障碍性血小板输注难治性

我们发现10例再生障碍性贫血患者中有8例在服用达拉单抗后血小板输注难治性得到缓解。值得注意的是，4名应答者实现了造血恢复，包括3名参与者显示了多系血细胞计数的改善，即使使用达拉单抗单药治疗（NCT05832216）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.